Search This Blog

Friday, June 20, 2025

'The legal status of assisted dying in different countries'

 British lawmakers will vote on Friday on whether to proceed with legislation to legalize assisted dying for the terminally ill, in what would be the biggest social reform in the country for a generation.

Below is a list of countries which let people choose to end their lives, or are considering doing so.

 

SWITZERLAND

Switzerland legalized assisted dying in 1942 on the condition the motive is not selfish, making it the first country in the world to permit the practice. A number of Swiss organizations such as Dignitas offer their services to foreign nationals.

 

UNITED STATES

Medical aid in dying, also known as physician assisted dying, is legal in 10 states: California, Colorado, Hawaii, Montana, Maine, New Jersey, New Mexico, Oregon, Vermont and Washington, plus the District of Columbia. Oregon was the first state to legalize it under a law which came into effect in 1997.

 

NETHERLANDS

The “Termination of Life on Request and Assisted Suicide (Review Procedures) Act” came into effect in 2002. A doctor is immune from punishment for euthanasia and assisted suicide where patients are experiencing “unbearable suffering with no prospect of improvement”. Minors can request euthanasia from the age of 12 but require parental permission before the age of 16.

 

BELGIUM

Belgium legalized medically assisted dying in 2002 for the terminally ill and for people experiencing unbearable suffering, which includes patients with psychiatric conditions. Since 2014, those under 18 who are terminally ill are covered by the law as long as they have parental permission.

 

CANADA

Canada introduced “Medical Assistance in Dying” in 2016 for those whose death was deemed to be “reasonably foreseeable”. Five years later, the law was extended to permit people with a “grievous and irremediable” medical condition to request assisted dying.

 

AUSTRALIA

Voluntary assisted dying for the terminally ill or those with a condition that is causing intolerable suffering is legal in most Australian states, after being introduced first in Victoria in 2019.

 

SPAIN

Spain approved a law in 2021 which allows euthanasia and medically assisted suicide for people with incurable or debilitating diseases who want to end their life.

 

GERMANY

Assisted dying had been legal in Germany until 2015 when the country outlawed its provision on an organized or commercial basis, effectively banning it in many cases. Five years later the country’s top court ruled in favor of groups providing terminally ill adults with assisted suicide services, but lawmakers are yet to finalize new rules.

 

FRANCE

Doctors in France have been allowed to put a person who is close to death and in great pain under deep sedation since 2016. But they were not allowed to administer life-ending medication.

French lawmakers voted in May 2025 to give some people in the later stages of a terminal illness the right to end their lives using a lethal substance, a law change supported by President Emmanuel Macron. The bill was approved by the National Assembly and is now being considered by the Senate. It could become law by 2027.

 

IRELAND

A cross-party Irish parliamentary committee recommended this year that the government should legalize assisted dying in certain restricted circumstances.

A majority of lawmakers in 2024 voted in favor of “noting” the committee’s findings. Steps could now be taken to consider a law change.

https://www.bworldonline.com/health/2025/06/20/680466/the-legal-status-of-assisted-dying-in-different-countries/

Bayer: towards a new indication for Nubeqa in Europe

 Bayer announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the approval of Nubeqa in a third indication for advanced prostate cancer.


This positive opinion concerns the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) in combination with anti-androgen hormone therapy (ADT).

Bayer says that this combination reduced the risk of radiographic disease progression or death by 46% in Phase III clinical trials compared to placebo and ADT.

The German pharmaceutical group adds that the CHMP's positive opinion reinforces Nubeqa's potential to become a standard treatment for various stages of prostate cancer, with or without chemotherapy, thereby expanding the therapeutic options available to physicians.

The European Commission's final decision on marketing authorization is expected in the coming months.

It should be noted that the US Food and Drug Administration (FDA) has also just approved Nubeqa for this indication.

Sam Altman says Meta tried to poach top OpenAI talent with $100M offers

 Meta Platforms has tried to lure top OpenAI talent with signing bonuses reaching $100 million and promises of even more generous annual compensation, according to OpenAI CEO Sam Altman.

“They (Meta) started making giant offers to a lot of people on our team,” Altman said on the “Uncapped” podcast released Tuesday.

“You know, like $100 million signing bonuses, more than that (in) compensation per year.”

OpenAI CEO Sam Altman claims that Meta has tried to poach his talented staffers with offers of up to $100 million.AFP via Getty Images

Despite the aggressive recruitment efforts, Altman noted that “at least, so far, none of our best people have decided to take them up on that.”

The Post has sought comment from OpenAI. A Meta representative declined to comment.

Altman framed the poaching attempts as part of a broader and intensifying battle for elite AI talent, likening the current climate to the free-agent frenzy of professional sports.

“I’ve heard that Meta thinks of us as their biggest competitor,” he said.

“Their current AI efforts have not worked as well as they have hoped and I respect being aggressive and continuing to try new things.”

The comments come at a pivotal moment in Meta’s artificial intelligence strategy. The company recently invested $14.3 billion in Scale AI and hired the startup’s founder, Alexandr Wang, to head up a new “superintelligence” division.

The much-ballyhooed “acquihire” deal included a 49% stake in Scale AI and saw a handful of Wang’s colleagues follow him to Meta.

Meta CEO Mark Zuckerberg has reportedly taken a personal interest in accelerating the company’s AI capabilities.

According to Bloomberg, Zuckerberg has directly participated in high-profile recruitment, including the recent hiring of Jack Rae, a leading researcher from DeepMind, Google’s AI research lab.

Meta CEO Mark Zuckerberg has taken a hands-on approach to building out his AI team due to frustration over the slow pace of development of his company’s flagship language model.AP

Altman, however, questioned whether throwing large sums of money at individuals creates the right environment for innovation.

“I think that there’s a lot of people, and Meta will be a new one, that are saying ‘We’re just going to try to copy OpenAI,’” he said.

“That basically never works. You’re always going to where your competitor was, and you don’t build up a culture of learning what it’s like to innovate.”

Altman said that so far none of his top-level employees have agreed to jump ship to Meta.REUTERS

Meta has historically championed open-source AI, particularly with its Llama series of large language models. Yet the company has faced setbacks.

The release of its newest flagship AI model was delayed amid internal concerns about its readiness, according to the Wall Street Journal.

Zuckerberg’s deep investment in AI infrastructure, however, has not gone unnoticed. Some industry observers argue that Meta is still playing a critical role in shaping the field.

Meta recently made a splash by acquiring a 49% stake in AI startup Scale AI — a move that resulted in CEO Alexandr Wang joining the tech giant.AP

“They basically built the rails for open source AI development, and so much of what is happening in AI is being built on Meta,” said Daniel Newman, CEO of Futurum Group, during an appearance on CNBC’s Power Lunch on Tuesday.

Meta’s open-source approach has enabled a wide range of third-party developers to build applications on top of its models. Proponents argue this could ultimately offer a counterbalance to the more closed strategies of rivals like OpenAI.

Meanwhile, OpenAI has been active on the M&A front as well. Last month, the company completed a $6.4 billion all-equity acquisition of io, a startup founded by former Apple design chief Jony Ive.

Ive has since joined OpenAI, bringing with him a design-forward approach to AI hardware and interfaces.

https://nypost.com/2025/06/18/business/openai-ceo-sam-altman-says-meta-offering-his-top-talent-100m-to-defect/

'European Investment Bank triples its financial commitment to defence'

With a new financial ceiling of €100 billion for 2025, the European Investment Bank (EIB) aims to invest in defence, energy networks and technology.

The European Investment Bank (EIB) is strengthening its role as the European Union's financial arm, with its financing ceiling for this year reaching €100 billion, a new record.

Against a backdrop of geopolitical tensions, the Bank is confirming its commitment to defence and security by tripling its lending. The EIB plans to devote 3.5% of total financing to the military sector. The institution mentions 32 flagship projects in the pipeline.

These announcements validate the extension in recent months of the EIB's security mandate, which marks a paradigm shift in the institution's mission.

This support will be available to all EU companies: public and private, large and small.

"We finance the public sector when it comes to infrastructure for large military barracks. Just this week we got the go-ahead to finance a very important piece of infrastructure in Lithuania, a military barracks that will house a brigade of the Bundeswehr (German army) very close to the Belarusian border," said EIB President Nadia Calviño.

"We are also financing large private companies for research and development programmes in the fields of innovation and industrial capacity," she added.

She also says that she is working with the European Commission to identify other key infrastructures for military mobility.

The climate priority

The EIB's commitment to defence does not, however, mean a complete turnaround. Climate change and clean energy remain priorities. The EIB deems climate action to go hand in hand with European security.

The Bank is therefore launching a new programme of investment in technology and innovation: TechEU. The scheme will provide €70 billion of equity, quasi-equity, loans and guarantees from the EIB Group between 2025 and 2027. It will also call on private capital to generate at least €250 billion of investment. The first wave of TechEU projects will be devoted to clean industries.

"This concerns the products needed to build energy networks. It's about guarantees for clean technology innovators. We also need to support the wind power industry and the deployment of power purchase agreements, which are essential to stabilise energy prices for Europe's major industries," said Calviño.

The EIB President stressed that the green transition and technology also contribute to the EU's strategic autonomy.

https://www.euronews.com/my-europe/2025/06/20/european-investment-bank-triples-its-financial-commitment-to-defence

Emergent BioSolutions (EBS) Added to Russell 3000 Index

 Emergent BioSolutions Inc. (NYSE: EBS) today announced the Company will be added to the broad-market Russell 3000® Index, effective after the U.S. market closes on June 27, 2025, as part of the annual reconstitution of the Russell U.S. stock indexes.

“Inclusion in the Russell 3000® Index is an important milestone in Emergent’s ongoing transformation,” said Joe Papa, president and chief executive officer of Emergent BioSolutions. “This recognition reflects the positive momentum we are building across the organization and helps to position us to enter a new phase of disciplined, sustainable growth in the year ahead. It also reaffirms our commitment to strong execution, financial stability, and long-term value creation for our shareholders.”

https://www.streetinsider.com/Corporate+News/Emergent+BioSolutions+%28EBS%29+Added+to+Russell+3000+Index/24957001.html

Lilly to appeal UK reimbursement denial for Alzheimer's drugs

 

Eli Lilly says it will appeal the decision after the UK health authorities refused to cover the cost of the Alzheimer’s drug Kisunla through the NHS.


The EU has previously refused to approve Kisunla, pointing out that the efficacy does not outweigh the risk of potentially fatal incidents. 


Sanofi and Regeneron’s Dupixent gets FDA approval for rare skin disease

 Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) Pharmaceuticals received Food and Drug Administration approval for their anti-inflammatory drug Dupixent to treat a rare skin disease, marking the eighth indication in the U.S. for this blockbuster medicine.

The FDA approved Dupixent on Friday as a treatment for adult patients with bullous pemphigoid, according to the companies.

This rare skin disease primarily affects elderly people and causes itching, blisters, lesions, and skin reddening.

The approval was based on results from a pivotal study that demonstrated more patients taking Dupixent achieved sustained disease remission and itch reduction compared to those on placebo.

The FDA evaluated the drug under priority review, a process reserved for medicines that may bring significant improvements to the treatment of serious conditions.

Bullous pemphigoid represents the eighth FDA-approved indication for Dupixent in the United States.

https://www.investing.com/news/stock-market-news/sanofi-and-regenerons-dupixent-gets-fda-approval-for-rare-skin-disease-93CH-4103292

Oil Prices Extend Losses As Iran Rejects Zero Enrichment As Conditions For US Talks

 A series of headlines, some contradictory, on where things stand with Iran nuclear negotiations with the US, sent oil sliding, then pumping, then extending losses again.

One senior Iranian official told Reuters that Iran is 'ready' to discuss limitations on its uranium enrichment, while a quick follow-up headline said "zero enrichment will undoubtedly be rejected" by Iran "especially now, under Israel's strikes."

The official said "the role of European powers is now more prominent, as Tehran is unwilling to engage with US amid Israeli attacks. After that glimmer of hope offered for negotiations, the clarification that nothing has in fact change, sent oil dropping further Friday morning.

Oil prices declined on Friday but stayed on track for a third straight weekly increase, following the White House’s postponement of a decision regarding US participation in the Israel-Iran conflict.

By 1000 GMT, Brent crude futures had dropped $1.89, or 2.4%, to $76.96 per barrel, though they remained poised for a weekly gain of nearly 4%.

According to the latest from Bloomberg:

Israel will complete the task of preventing Iran from gaining nuclear weapons whether or not the US joins the operation, its energy minister said. Iranian President Masoud Pezeshkian said the only way to end the war is to “unconditionally” stop Israel.

developing...

https://www.zerohedge.com/energy/oil-prices-extend-losses-iran-rejects-zero-enrichment-conditions-us-talks